Similar articles

• Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature.

  Voeten DM, den Bakker CM, Heineman DJ, Ket JCF, Daams F, van der Peet DL. Voeten DM, et al. World J Surg. 2019 May;43(5):1271-1285. doi: 10.1007/s00268-018-04901-z. World J Surg. 2019. PMID: 30607604
• Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.

  Hategan M, Cook N, Prewett S, Hindmarsh A, Qian W, Gilligan D. Hategan M, et al. Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27. Dis Esophagus. 2015. PMID: 24863560 Review.
• Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.

  Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D. Barbetta A, et al. J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3. doi: 10.1016/j.jtcvs.2018.01.086. Epub 2018 Feb 15. J Thorac Cardiovasc Surg. 2018. PMID: 29548582 Free PMC article.
• Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.

  Lin WC, Ding YF, Hsu HL, Chang JH, Yuan KS, Wu ATH, Chow JM, Chang CL, Chen SU, Wu SY. Lin WC, et al. Cancer. 2017 Oct 15;123(20):3904-3915. doi: 10.1002/cncr.30823. Epub 2017 Jun 13. Cancer. 2017. PMID: 28608916
• Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

  Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS. Jeong Y, et al. J Surg Oncol. 2014 Apr;109(5):472-7. doi: 10.1002/jso.23514. Epub 2013 Dec 2. J Surg Oncol. 2014. PMID: 24301552